MRNA Oct 2024 110.000 call
| Previous Close | 17.45 |
| Open | 21.27 |
| Bid | 22.30 |
| Ask | 23.20 |
| Strike | 110.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 20.28 - 23.48 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 58 |
- Yahoo Finance Video
Moderna CEO on the changing COVID market: Pandemic to endemic
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy developing updated coronavirus vaccines for the 2024-2025 season and recently announced an expansion into the Brazilian market. As the coronavirus pandemic has shifted toward an endemic, Bancel explains how Moderna continues to innovate, sharing a positive outlook on phase two data for a combination flu and coronavirus vaccine. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Investor's Business DailyModerna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.
Barrons.comModerna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Moderna reported first-quarter financial results Thursday that soundly beat Wall Street expectations, but the focus for investors remains on the anticipated launch of the company’s second product later this year. Moderna anticipates offering a respiratory syncytial virus vaccine later this year, to compete against vaccines for the same condition that GSK and Pfizer brought to the market in 2023. Moderna’s revenue for the first quarter were $167 million, well ahead of the $93 million consensus estimate as calculated by FactSet.
